Sangamo Therapeutics Inc. (NASDAQ:SGMO) finished Wednesday with a subtraction of -$0.09 to close at $1.05, a downside of -7.89 percent. An average of 1,377,360 shares of common stock have been traded in the last five days. There was a fall of -$0.1900 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 1,633,870 shares traded, while the 50-day average volume stands at 2,263,678.
SGMO stock has decreased by -24.46% in the last month. The company shares reached their 1-month lowest point of $1.0450 on 08/09/23. With the stock rallying to its 52-week high on 01/13/23, shares of the company touched a low of $1.07 and a high of $6.42 in 52 weeks. It has reached a new high 6 times so far this year and lost -66.56% or -$2.0900 in price. In spite of this, the price is down -83.64% from the 52-week high.
Insider Transactions
SGMO stock investors should be aware that Sangamo Therapeutics Inc. (SGMO) stock had its last reported insider trading activity 345 days ago on Aug 30. In this transaction, the insider spent $526,520. 10% Owner, BIOGEN INC., disposed of 400,000 shares at a price of $5.33 on Aug 29. The insider now owns more than $2,130,720 worth of shares.
Valuation Metrics
Sangamo Therapeutics Inc. (SGMO) stock’s beta is 1.09. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.76, the price-to-book (PB) ratio at 0.53.
Financial Health
The quick ratio of Sangamo Therapeutics Inc. for the three months ended June 29 was 3.90, and the current ratio was 3.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Sangamo Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -169.97%, while its operating margin for the same period stands at -57.20%. Its gross profit as reported stood at $312.58 million compared to revenue of $111.3 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Sangamo Therapeutics Inc.’s return on assets was -23.00%.
Earnings Surprise
For the three-month period that ended June 29, Sangamo Therapeutics Inc. had $76.27 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$114.51 million in the quarter, while revenues of $21.13 million were grew 62.3%. The analyst consensus anticipated Sangamo Therapeutics Inc.’s latest quarter earnings to come in at -$0.34 per share, but it turned out to be -$0.66, a -94.10% surprise. For the quarter, EBITDA amounted to -$66.86 million. At the end of the quarter ending June 29, Sangamo Therapeutics Inc.’s stock balance sheet showed total liabilities of 91.43 million. Shareholders own equity worth $177.11 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Sangamo Therapeutics Inc. (SGMO) price momentum. RSI 9-day as of the close on 09 August was 24.77%, suggesting the stock is oversold, with historical volatility in this time frame at 65.58%.
As of today, SGMO’s price is $1.1480 -15.32% or -$0.1900 from its 5-day moving average. SGMO is currently trading -26.57% lower than its 20-day SMA and -50.70% lower than its 100-day SMA. However, the stock’s current price level is -16.67% below the SMA50 and -75.64% below the SMA200.
The stochastic %K and %D were 4.32% and 4.69%, respectively, and the average true range (ATR) was 0.0852. With the 14-day stochastic at 1.23% and the average true range at 0.0924, the RSI (14) stands at 32.72%. The stock has reached -0.0906 on the 9-day MACD Oscillator while the 14-day reading was at -0.1304.
Analyst Ratings
BofA Securities downgraded Sangamo Therapeutics Inc. (NASDAQ: SGMO) to a an Underperform rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Sangamo Therapeutics Inc. (SGMO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell SGMO, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 5 others rate it as a “buy”.
What is SGMO’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $9.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Sangamo Therapeutics Inc. (SGMO) stock is $7.20.
